
-
Context Therapeutics NasdaqCM:CNTX Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Location: 2001 Market Street, Suite 200, Philadelphia, PA, 19103, United States | Website: https://www.contexttherapeutics.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-33.79M
Cash
89.35M
Avg Qtr Burn
-3.806M
Short % of Float
5.75%
Insider Ownership
2.33%
Institutional Own.
79.64%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
CT-95 Details Solid tumor/s | Phase 1 Data readout | |
CTIM-76 Details Solid tumor/s, Testicular cancer, Cervical cancer, Ovarian cancer | Phase 1 Data readout | |
ONA-XR Details Metastatic breast cancer to brain, ER+/HER2- breast cancer, Breast cancer, Cancer, Solid tumor/s | Failed Discontinued | |
ONA-XR Details Solid tumor/s, Cancer, Ovarian cancer, Endometrial cancer | Failed Discontinued | |
ONA-XR Details Breast cancer, Cancer, Solid tumor/s, Metastatic breast cancer to brain, ER+/HER2- breast cancer | Failed Discontinued |